Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report specifically addresses notifications regarding transactions of directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the share price of £12.82 per share used for dividend reinvestment.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing details an increase in share interests for specific individuals following the reinvestment of dividends paid on January 8, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory notification of director share transactions in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Dividend reinvestment occurred on January 8, 2009, at a price of £12.82 per share.
- Specific increases in shareholdings were recorded for Mr. E J Gray (245.32 shares), Mr. S A Hussain (439.71 shares), Mr. D S Redfern (194.07 shares), and Ms. C Thomas (121.29 shares).
- The report was signed by Victoria Whyte, Authorised Signatory, on January 14, 2009.